Key Data & Figures
In 2025, Almirall experienced a transformative year driven by accelerated growth, strengthening its leadership in medical dermatology and surpassing a key milestone with net sales exceeding €1 billion. The strong performance of its portfolio and progress in its pipeline supported broader access to differentiated treatments and reinforced its R&D capabilities, laying the foundation for sustained, profitable long-term growth.
€1,108.1 MM
(+12.4% YoY)
Net sales
€232.9 MM
(+20.9% YoY)
EBITDA
€52.6MM
(+105.5% YoY)
Normalized net income
Patients at the core
A year of groundbreaking achievements
Major Milestones in 2025
Entering a new era of sustained growth with our focus on medical dermatology
Find out more
Our ambition is built on four pillars
Our strategy is guided by our purpose of transforming patients’ lives, helping them achieve a healthy life. As a family-owned company, we adopt a long-term vision that drives innovation in dermatology, scientific collaboration, and a responsible approach to sustainability and governance.
